A comparison of tacrolimus and cyclosporine combined with methotrexate for graft-versus-host disease prophylaxis, stratified by stem cell source: a retrospective nationwide survey

Rika Sakai, Masataka Taguri, Kumi Oshima, Takehiko Mori, Hiroatsu Ago, Souichi Adachi, Satoshi Morita, Shuichi Taniguchi, Takahiro Fukuda, Kazuteru Ohashi, Tetsuya Eto, Koichi Miyamura, Koji Iwato, Naoki Kobayashi, Heiwa Kanamori, Yasuo Morishima, Tokiko Nagamura-Inoue, Hisashi Sakamaki, Yoshiko Atsuta, Makoto Murata

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

This nationwide, retrospective study compared the efficacy of cyclosporine and tacrolimus with methotrexate (CsA/MTX and TAC/MTX) for acute graft-versus-host disease (aGVHD) prevention and transplant-related outcomes. Data were obtained from the Transplant Registry Unified Management Program of the Japan Society for Hematopoietic Cell Transplantation for ≥16-year-old leukemia patients who received CsA/MTX or TAC/MTX after bone marrow transplantation and peripheral blood stem cell transplantation from serological HLA-matched related donors (MRD), HLA 8/8 allele-matched, or one allele-mismatched unrelated bone marrow (UBM), or 0–2 antigen-mismatched unrelated cord blood (UCB) transplantation between January 2005 and December 2009. Separate analyses were performed for each cohort. Adjusted multivariate analyses indicated that in the MRD (n = 1524) and the UBM (n = 1466) cohorts, TAC/MTX significantly reduced grade II–IV aGVHD risk (HR 0.58, P = 0.006 and HR 0.77, P = 0.015, respectively) without affecting the other transplant-related outcomes. In the UCB cohort (n = 925), TAC/MTX significantly reduced the risk of non-relapse mortality (HR 0.63, P = 0.027) and chronic GVHD (HR 0.60, P = 0.02) without significant effects on grade II–IV aGVHD (HR 0.83, P = 0.21). Our results may provide the most up-to-date data regarding GVHD prevention in Japan.

Original languageEnglish
Pages (from-to)322-333
Number of pages12
JournalInternational Journal of Hematology
Volume103
Issue number3
DOIs
Publication statusPublished - 2016 Mar 1

Fingerprint

Tacrolimus
Graft vs Host Disease
Methotrexate
Cyclosporine
Stem Cells
Transplants
Fetal Blood
Japan
Bone Marrow
Alleles
Tissue Donors
Peripheral Blood Stem Cell Transplantation
Cell Transplantation
Bone Marrow Transplantation
Registries
Leukemia
Multivariate Analysis
Retrospective Studies
Transplantation
Antigens

Keywords

  • Cyclosporine
  • Graft-versus-host disease
  • Methotrexate
  • Tacrolimus

ASJC Scopus subject areas

  • Hematology

Cite this

A comparison of tacrolimus and cyclosporine combined with methotrexate for graft-versus-host disease prophylaxis, stratified by stem cell source : a retrospective nationwide survey. / Sakai, Rika; Taguri, Masataka; Oshima, Kumi; Mori, Takehiko; Ago, Hiroatsu; Adachi, Souichi; Morita, Satoshi; Taniguchi, Shuichi; Fukuda, Takahiro; Ohashi, Kazuteru; Eto, Tetsuya; Miyamura, Koichi; Iwato, Koji; Kobayashi, Naoki; Kanamori, Heiwa; Morishima, Yasuo; Nagamura-Inoue, Tokiko; Sakamaki, Hisashi; Atsuta, Yoshiko; Murata, Makoto.

In: International Journal of Hematology, Vol. 103, No. 3, 01.03.2016, p. 322-333.

Research output: Contribution to journalArticle

Sakai, R, Taguri, M, Oshima, K, Mori, T, Ago, H, Adachi, S, Morita, S, Taniguchi, S, Fukuda, T, Ohashi, K, Eto, T, Miyamura, K, Iwato, K, Kobayashi, N, Kanamori, H, Morishima, Y, Nagamura-Inoue, T, Sakamaki, H, Atsuta, Y & Murata, M 2016, 'A comparison of tacrolimus and cyclosporine combined with methotrexate for graft-versus-host disease prophylaxis, stratified by stem cell source: a retrospective nationwide survey', International Journal of Hematology, vol. 103, no. 3, pp. 322-333. https://doi.org/10.1007/s12185-016-1939-9
Sakai, Rika ; Taguri, Masataka ; Oshima, Kumi ; Mori, Takehiko ; Ago, Hiroatsu ; Adachi, Souichi ; Morita, Satoshi ; Taniguchi, Shuichi ; Fukuda, Takahiro ; Ohashi, Kazuteru ; Eto, Tetsuya ; Miyamura, Koichi ; Iwato, Koji ; Kobayashi, Naoki ; Kanamori, Heiwa ; Morishima, Yasuo ; Nagamura-Inoue, Tokiko ; Sakamaki, Hisashi ; Atsuta, Yoshiko ; Murata, Makoto. / A comparison of tacrolimus and cyclosporine combined with methotrexate for graft-versus-host disease prophylaxis, stratified by stem cell source : a retrospective nationwide survey. In: International Journal of Hematology. 2016 ; Vol. 103, No. 3. pp. 322-333.
@article{c8e76703f4c949f68b4eacf67f7230d2,
title = "A comparison of tacrolimus and cyclosporine combined with methotrexate for graft-versus-host disease prophylaxis, stratified by stem cell source: a retrospective nationwide survey",
abstract = "This nationwide, retrospective study compared the efficacy of cyclosporine and tacrolimus with methotrexate (CsA/MTX and TAC/MTX) for acute graft-versus-host disease (aGVHD) prevention and transplant-related outcomes. Data were obtained from the Transplant Registry Unified Management Program of the Japan Society for Hematopoietic Cell Transplantation for ≥16-year-old leukemia patients who received CsA/MTX or TAC/MTX after bone marrow transplantation and peripheral blood stem cell transplantation from serological HLA-matched related donors (MRD), HLA 8/8 allele-matched, or one allele-mismatched unrelated bone marrow (UBM), or 0–2 antigen-mismatched unrelated cord blood (UCB) transplantation between January 2005 and December 2009. Separate analyses were performed for each cohort. Adjusted multivariate analyses indicated that in the MRD (n = 1524) and the UBM (n = 1466) cohorts, TAC/MTX significantly reduced grade II–IV aGVHD risk (HR 0.58, P = 0.006 and HR 0.77, P = 0.015, respectively) without affecting the other transplant-related outcomes. In the UCB cohort (n = 925), TAC/MTX significantly reduced the risk of non-relapse mortality (HR 0.63, P = 0.027) and chronic GVHD (HR 0.60, P = 0.02) without significant effects on grade II–IV aGVHD (HR 0.83, P = 0.21). Our results may provide the most up-to-date data regarding GVHD prevention in Japan.",
keywords = "Cyclosporine, Graft-versus-host disease, Methotrexate, Tacrolimus",
author = "Rika Sakai and Masataka Taguri and Kumi Oshima and Takehiko Mori and Hiroatsu Ago and Souichi Adachi and Satoshi Morita and Shuichi Taniguchi and Takahiro Fukuda and Kazuteru Ohashi and Tetsuya Eto and Koichi Miyamura and Koji Iwato and Naoki Kobayashi and Heiwa Kanamori and Yasuo Morishima and Tokiko Nagamura-Inoue and Hisashi Sakamaki and Yoshiko Atsuta and Makoto Murata",
year = "2016",
month = "3",
day = "1",
doi = "10.1007/s12185-016-1939-9",
language = "English",
volume = "103",
pages = "322--333",
journal = "International Journal of Hematology",
issn = "0925-5710",
publisher = "Springer Japan",
number = "3",

}

TY - JOUR

T1 - A comparison of tacrolimus and cyclosporine combined with methotrexate for graft-versus-host disease prophylaxis, stratified by stem cell source

T2 - a retrospective nationwide survey

AU - Sakai, Rika

AU - Taguri, Masataka

AU - Oshima, Kumi

AU - Mori, Takehiko

AU - Ago, Hiroatsu

AU - Adachi, Souichi

AU - Morita, Satoshi

AU - Taniguchi, Shuichi

AU - Fukuda, Takahiro

AU - Ohashi, Kazuteru

AU - Eto, Tetsuya

AU - Miyamura, Koichi

AU - Iwato, Koji

AU - Kobayashi, Naoki

AU - Kanamori, Heiwa

AU - Morishima, Yasuo

AU - Nagamura-Inoue, Tokiko

AU - Sakamaki, Hisashi

AU - Atsuta, Yoshiko

AU - Murata, Makoto

PY - 2016/3/1

Y1 - 2016/3/1

N2 - This nationwide, retrospective study compared the efficacy of cyclosporine and tacrolimus with methotrexate (CsA/MTX and TAC/MTX) for acute graft-versus-host disease (aGVHD) prevention and transplant-related outcomes. Data were obtained from the Transplant Registry Unified Management Program of the Japan Society for Hematopoietic Cell Transplantation for ≥16-year-old leukemia patients who received CsA/MTX or TAC/MTX after bone marrow transplantation and peripheral blood stem cell transplantation from serological HLA-matched related donors (MRD), HLA 8/8 allele-matched, or one allele-mismatched unrelated bone marrow (UBM), or 0–2 antigen-mismatched unrelated cord blood (UCB) transplantation between January 2005 and December 2009. Separate analyses were performed for each cohort. Adjusted multivariate analyses indicated that in the MRD (n = 1524) and the UBM (n = 1466) cohorts, TAC/MTX significantly reduced grade II–IV aGVHD risk (HR 0.58, P = 0.006 and HR 0.77, P = 0.015, respectively) without affecting the other transplant-related outcomes. In the UCB cohort (n = 925), TAC/MTX significantly reduced the risk of non-relapse mortality (HR 0.63, P = 0.027) and chronic GVHD (HR 0.60, P = 0.02) without significant effects on grade II–IV aGVHD (HR 0.83, P = 0.21). Our results may provide the most up-to-date data regarding GVHD prevention in Japan.

AB - This nationwide, retrospective study compared the efficacy of cyclosporine and tacrolimus with methotrexate (CsA/MTX and TAC/MTX) for acute graft-versus-host disease (aGVHD) prevention and transplant-related outcomes. Data were obtained from the Transplant Registry Unified Management Program of the Japan Society for Hematopoietic Cell Transplantation for ≥16-year-old leukemia patients who received CsA/MTX or TAC/MTX after bone marrow transplantation and peripheral blood stem cell transplantation from serological HLA-matched related donors (MRD), HLA 8/8 allele-matched, or one allele-mismatched unrelated bone marrow (UBM), or 0–2 antigen-mismatched unrelated cord blood (UCB) transplantation between January 2005 and December 2009. Separate analyses were performed for each cohort. Adjusted multivariate analyses indicated that in the MRD (n = 1524) and the UBM (n = 1466) cohorts, TAC/MTX significantly reduced grade II–IV aGVHD risk (HR 0.58, P = 0.006 and HR 0.77, P = 0.015, respectively) without affecting the other transplant-related outcomes. In the UCB cohort (n = 925), TAC/MTX significantly reduced the risk of non-relapse mortality (HR 0.63, P = 0.027) and chronic GVHD (HR 0.60, P = 0.02) without significant effects on grade II–IV aGVHD (HR 0.83, P = 0.21). Our results may provide the most up-to-date data regarding GVHD prevention in Japan.

KW - Cyclosporine

KW - Graft-versus-host disease

KW - Methotrexate

KW - Tacrolimus

UR - http://www.scopus.com/inward/record.url?scp=84959528041&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84959528041&partnerID=8YFLogxK

U2 - 10.1007/s12185-016-1939-9

DO - 10.1007/s12185-016-1939-9

M3 - Article

C2 - 26800676

AN - SCOPUS:84959528041

VL - 103

SP - 322

EP - 333

JO - International Journal of Hematology

JF - International Journal of Hematology

SN - 0925-5710

IS - 3

ER -